Last reviewed · How we verify

AC-150A 0.1%

Aciex Therapeutics, Inc. · Phase 2 active Small molecule

AC-150A 0.1% is a topical corticosteroid Small molecule drug developed by Aciex Therapeutics, Inc.. It is currently in Phase 2 development for Seborrheic dermatitis, Psoriasis.

AC-150A 0.1% is a topical corticosteroid used to reduce inflammation and itching in various skin conditions.

AC-150A 0.1% is a topical corticosteroid used to reduce inflammation and itching in various skin conditions. Used for Seborrheic dermatitis, Psoriasis.

Likelihood of approval
15.3% vs 15.3% industry baseline
If approved by FDA: likely 2031–2034
Steps remaining: Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 2 → approval rate +15.3pp
    Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2031–2034 —
EMA EU 2032–2035 +0.7 yr
MHRA GB 2032–2035 +0.7 yr
Health Canada CA 2032–2036 +0.9 yr
TGA AU 2032–2036 +1.2 yr
PMDA JP 2032–2036 +1.5 yr
NMPA CN 2033–2037 +2.3 yr
MFDS KR 2032–2036 +1.4 yr
CDSCO IN 2032–2037 +1.8 yr
ANVISA BR 2033–2037 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameAC-150A 0.1%
SponsorAciex Therapeutics, Inc.
Drug classtopical corticosteroid
ModalitySmall molecule
Therapeutic areaDermatology
PhasePhase 2

Mechanism of action

It works by inhibiting the production of inflammatory mediators and reducing the migration of inflammatory cells to the affected area. This leads to a decrease in the symptoms associated with skin inflammation, such as redness, swelling, and itching.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about AC-150A 0.1%

What is AC-150A 0.1%?

AC-150A 0.1% is a topical corticosteroid drug developed by Aciex Therapeutics, Inc., indicated for Seborrheic dermatitis, Psoriasis.

How does AC-150A 0.1% work?

AC-150A 0.1% is a topical corticosteroid used to reduce inflammation and itching in various skin conditions.

What is AC-150A 0.1% used for?

AC-150A 0.1% is indicated for Seborrheic dermatitis, Psoriasis.

Who makes AC-150A 0.1%?

AC-150A 0.1% is developed by Aciex Therapeutics, Inc. (see full Aciex Therapeutics, Inc. pipeline at /company/aciex-therapeutics-inc).

What drug class is AC-150A 0.1% in?

AC-150A 0.1% belongs to the topical corticosteroid class. See all topical corticosteroid drugs at /class/topical-corticosteroid.

What development phase is AC-150A 0.1% in?

AC-150A 0.1% is in Phase 2.

What are the side effects of AC-150A 0.1%?

Common side effects of AC-150A 0.1% include Skin atrophy, Hypopigmentation.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing